ArticleJournal of biochemical and molecular toxicology2026
Synthesis, Characterization, and Cytotoxic Activity Properties of Some Novel Purine Derivatives.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study reports the synthesis of nine new compounds with purine scaffolds. It thoroughly analyzes them using a variety of spectroscopic methods, including high-resolution mass spectrometry (HR-MS), proton nuclear magnetic resonance (¹H NMR), attached proton test nuclear magnetic resonance (¹³C APT NMR), and fourier-transform infrared spectroscopy (FT-IR). The in vitro cytotoxic potential of these compounds was examined using two cancer cell lines: MDA-MB-231, a model of triple-negative breast cancer, and HepG2, a model of liver carcinoma. Furthermore, compounds were tested in a normal mouse fibroblast cell line (L929). Biological screening revealed that two of the synthesized molecules, ethyl 2-(2-(2-(9H-purin-6-yl)hydrazineylidene)-3-(4-methylphenyl)-4-oxothiazolidin-5-ylidene)acetate (4b) and ethyl 2-(2-(2-(9H-purin-6-yl)hydrazineylidene)-3-(4-nitrophenyl)-4-oxothiazolidin-5-ylidene)acetate (4c) exerted cytotoxic effects with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.